Soroban Capital Partners Picked Up Praxair Inc. (NYSE:PX) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Praxair Inc. (NYSE:PX) reported that Soroban Capital Partners has picked up 17,619,237 of common stock as of 2017-04-27.
The acquisition brings the aggregate amount owned by Soroban Capital Partners to a total of 17,619,237 representing less than 6.2% stake in the company.
For those not familiar with the company, Praxair, Inc. is an industrial gas company. The Company’s operations are organized into five segments, four of which have been determined on a geographic basis of segmentation: North America, Europe, South America and Asia. In addition, it operates its surface technologies business through its subsidiary, Praxair Surface Technologies, Inc., which represents the fifth segment. Its operations consist of two product lines: industrial gases and surface technologies. Its industrial gases product line centers on the manufacturing and distribution of atmospheric gases (oxygen, nitrogen, argon, rare gases) and process gases (carbon dioxide, helium, hydrogen, electronic gases, specialty gases). It also designs, engineers and builds equipment that produces industrial gases primarily for internal use. Its Surface Technologies segment, operated through Praxair Surface Technologies, Inc., supplies wear-resistant and high-temperature corrosion-resistant metallic and ceramic coatings and powders.
A glance at Praxair Inc. (NYSE:PX)’s key stats reveals a current market capitalization of 36.02 Billion based on 285.28 Million shares outstanding and a price at last close of $125.81 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-01-07, Angel picked up 5,000 at a purchase price of $97.25. This brings their total holding to 133,748 as of the date of the filing.
On the sell side, the most recent transaction saw Angel unload 83,300 shares at a sale price of $119.04. This brings their total holding to 37,389.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Praxair Inc. (NYSE:PX) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Guess Who Picked Eagle Bulk Shipping Inc. (NASDAQ:EGLE) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Eagle Bulk Shipping Inc. (NASDAQ:EGLE) reported that Ac Maritime, Ltd. has picked up 3,333,333 of common stock as of 2017-04-27.
The acquisition brings the aggregate amount owned by Ac Maritime, Ltd. to a total of 3,333,333 representing less than 6.9% stake in the company.
For those not familiar with the company, Eagle Bulk Shipping Inc. (NASDAQ: EGLE) is a US-based owner and operator of dry bulk vessels, providing its customers with reliable and responsible global transportation services for the carriage of bulk commodities including: coal, grain, iron ore, steel, cement, and forest products, among others. Our owned fleet currently totals 40 vessels, all of which are focused on the mid-size asset class, referred to as Supramax. These vessels are between 50,000 and 59,000 deadweight tons and are ‘geared’, meaning they are equipped with onboard cranes allowing for the self-loading and unloading of cargoes. This feature distinguishes them from the larger classes of bulk carriers and provides greatly enhanced flexibility and versatility – both with respect to cargo diversity and port accessibility. Eagle operates 39 Supramax, 1 Handymax (48,000 deadweight) and 1 Handysize logs-fitted bulk carrier (37,000 deadweight), both of which are also geared.
A glance at Eagle Bulk Shipping Inc. (NASDAQ:EGLE)’s key stats reveals a current market capitalization of 364.59 Million based on 74.10 Million shares outstanding and a price at last close of $4.82 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-01-20, Oaktree picked up 7,600,000 at a purchase price of $4.50. This brings their total holding to 23,017,928 as of the date of the filing.
On the sell side, the most recent transaction saw Davidson unload 100,000 shares at a sale price of $9.18. This brings their total holding to 3,801,340.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Eagle Bulk Shipping Inc. (NASDAQ:EGLE) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Why NanoViricides Inc (NYSEMKT:NNVC) Shares Could Recover Soon
NanoViricides Inc (NYSEMKT:NNVC) shares dipped 2.61% on Wednesday to $1.12 and were unchanged in after-hours trading. Share prices have been trading in a 52-week range of $1.03 to $2.18. The company has a market cap of $72.89 million at 62.82 million shares outstanding.
NanoViricides Inc is a nano-biopharmaceutical company with several drugs in various stages of development. The company focuses on its research and clinical programs on specific anti-viral therapeutics. It is engaged in the application of nanomedicine technologies to the issues of viral diseases.
Its nanoviricide technology enables direct attacks at multiple points on a virus particle. In addition, the nanoviricide technology also simultaneously enables attacking the intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients within the core of the nanoviricide. The nanoviricide technology is engaged in both attacking extracellular virus thereby breaking the reinfection cycle, and simultaneously disrupting intracellular production of the virus, thereby enabling complete control of a virus infection.
In a press release, NanoViricides Inc shared that Eugene Seymour, MD, MPH, CEO, will present information about the company and its progress towards human trials at the Planet Microcap conference at the Planet Hollywood Hotel later today. This Planet MicroCap Showcase brings together the most promising companies and the top dealmakers in MicroCap Finance for three days of company presentations, one-on-one meetings, and networking.
The company has previously reported that its broad spectrum anti-herpesvirus drug candidates were highly effective in treating HSV-1 infection in a lethal animal model. It has since improved on its Herpecide technology, which ncludes development of skin cream/lotion for the treatment of herpes labialis typically caused by HSV-1, genital lesions typically caused by HSV-2, shingles caused by reactivation of the human herpesvirus-3 and eye drops or gel for the treatment of herpes keratitis of the external eye.
In particular, NanoViricides Inc believes that its drug candidate for the topical treatment of shingles would have the fastest drug development path towards human clinical trials. It has also been working on scaling up production of this drug candidate with the goal of developing 500g to 1kg per batch production capability.
Apart from this, the company has eight different drugs in development, including four indications in the HerpeCide program. It is one of a few bio-pharma companies that has all the capabilities needed from research and development to marketable drug manufacture in the small quantities needed for human clinical trials. All the biological testing and characterization of these drug candidates continues to be performed by external academic or institutional collaborators and contract research organizations.
DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.